CSIMarket


Bionano Genomics Inc   (BNGO)
Other Ticker:  
 


 

Bionano Genomics Inc

BNGO's Financial Statements and Analysis



Bionano Genomics Inc increased third quarter of 2023 net loss per share of $-3.22 compare to net loss per share of $-0.11 recorded in the same quarter a year ago a decrease compare to $-1.24 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -3.22 $  9 Mill
$-3.11     $+2M     +29.04 %



Bionano Genomics Inc 's Revenue rose by 29.04 % in third quarter of 2023 (Sep 30 2023) year on year, to $9 million and advanced by 7.57 % sequentially.


Bionano Genomics Inc is

More on BNGO's Income Statement



Bionano Genomics Inc 's in thethird quarter of 2023 recorded net loss of $-112.566 million, an increase from net loss of $-31.809 million in III. Quarter a year ago.

Sequentially net loss advanced

More on BNGO's Growth

Bionano Genomics Inc Inventories
BNGO's Cash flow In the third quarter of 2023 company's net cash flow was $20 million


Bionano Genomics Inc does not pay out common stock dividend.

In trailing twelve-month period Bionano Genomics Inc payed $ -3.71 cash per share, on a free-cash flow basis .

Book value fell by -50.13 % sequentially to $3.40 per share, -72.63% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.38 per share from $ 3.17.

Company issued 3.50 million shares or 11.12 % in Sep 30 2023.


More on BNGO's Dividends

 Market Capitalization (Millions) 36
 Shares Outstanding (Millions) 35
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 34
 Net Income (TTM) (Millions $) -227
 Cash Flow (TTM) (Millions $) 26
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Bionano Genomics Inc does not pay out common stock dividend.

In trailing twelve-month period Bionano Genomics Inc had negative $ -3.71 cash flow per share, on a free-cash flow basis .

Book value fell by -50.13 % sequentially to $3.40 per share, -72.63% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.38 per share from $ 3.17.

Company issued 3.50 million shares or 11.12 % in Sep 30 2023.


More on BNGO's Balance Sheets

 Market Capitalization (Millions) 36
 Shares Outstanding (Millions) 35
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 34
 Net Income (TTM) (Millions $) -227
 Cash Flow (TTM) (Millions $) 26
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Bionano Genomics Inc Earnings

Bionano Genomics Inc Experiences Remarkable Surge in Revenue, Paving the Way for a Promising Fiscal Period 2.

Bionano Genomics Inc Shines Among Laboratory Analytical Instruments Industry
The Laboratory Analytical Instruments industry has experienced a challenging period, with most companies reporting business contraction. However, Bionano Genomics Inc (BNGO) defies this downward trend by posting a significant surge in revenue, demonstrating its resilience and growth potential. Despite a shortfall per share increase, BNGO's positive financial performance is noteworthy for investors seeking opportunities in this sector.
In its most recent fiscal period, BNGO reported a remarkable 29.04% increase in revenue to $9.32 million compared to the same reporting period the previous year. This growth sets the company ap...

Despite Surge in Revenue, Bionano Genomics Inc Falls Short of Profitability in Q2 2023

Bionano Genomics Inc Reports Surge in Revenue but Increased Loss per Share
Investors in the Biotechnology and Pharmaceuticals industry received positive news as Bionano Genomics Inc announced a significant surge in revenue during the April to June 30, 2023 quarter. The company reported a revenue increase of 29.865% to $8.66 million compared to the same reporting season a year before.
However, despite the revenue growth, Bionano Genomics also revealed an increase in loss per share, which stood at $-1.24 per share. This marks a sequential surge in loss from $-0.12 per share. Although the revenue improved by 16.817% from $7.42 million, the company still realized a net loss of $-38.912 million for the A...

Bionano Genomics Inc: Struggling to Turn Revenue Surge into Profitability

Investors in the Biotechnology and Pharmaceuticals industry might be interested in the recent financial results of Bionano Genomics Inc. The company reported a surge in revenue of 30.179% to $7.42 million in the financial time-frame ending March 31, 2023, compared to the same period a year ago. However, the company's deficit has swelled at $-0.12 per share, slightly better than the previous year's $-0.13 per share.
The news is not all good, as Bionano Genomics Inc reported a net loss of $-37.124 million in the first quarter of 2023, compared to $-29.952 million a year ago. Despite these results, the company is expected to report its next financial earnings on August 03, 2023, which may provide more insi...


Date modified: 2023-11-09T22:31:20+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com